|
 |
안명주 (Myung-Ju Ahn)
성균관대학교 의과대학
CV PDF 792 KB
 관련인물  |
|
|
|
|
|
|
|
|
| A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy |
| Ann. Oncol., Available online 5 July 2020 | https://doi.org/10.1016/j.annonc.2020.06.017 |
| Cancer Biology/Oncology ( 2020-07-06 ) | 한빛사논문 |
|
|
|
|
|
| 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial |
| J. Thorac. Oncol., Volume 11, Issue 4, Supplement, April 2016, Page S115 | https://doi.org/10.1016/S1556-0864(16)30246-5 |
| ( 2020-06-08 ) | 상위피인용논문 |
|
|
|
|
|
|
|
|
|
| Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma |
| Nat. Commun., Published: 08 May 2020 11, Article number: 2285 (2020) | https://doi.org/10.1038/s41467-020-16164-1 |
| Bioinformatics, Cancer Biology/Oncology, Genomics ( 2020-05-11 ) | 한빛사논문 |
|
|
|
|
|
| Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study |
| J. Clin. Oncol., Published online : December 06, 2019 | DOI: 10.1200/JCO.19.00457 |
| Cancer Biology/Oncology ( 2019-12-13 ) | 한빛사논문 |
|
|
|
|
| |
|
| Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) |
| J. Clin. Oncol., Published online : December 11, 2019 | DOI: 10.1200/JCO.19.00931 |
| Cancer Biology/Oncology ( 2019-12-13 ) | 한빛사논문 |
|
|
|
|
|
|
| Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study |
| Lancet Oncol., Available online 3 October 2019 | https://doi.org/10.1016/S1470-2045(19)30504-2 |
| Cancer Biology/Oncology ( 2019-10-04 ) | 한빛사논문 |
|
|
|
|
|
|
|
| The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors |
| Clin. Cancer Res., Published Online First January 15, 2019 | doi: 10.1158/1078-0432.CCR-18-1449 |
| Cancer Biology/Oncology ( 2019-01-17 ) | 한빛사논문 |
|
|
|
|
|
|
| Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial |
| J. Clin. Oncol., Published online before print June 15, 2018 | https://doi.org/10.1200/JCO.2017.77.3184 |
| Cancer Biology/Oncology ( 2018-06-19 ) | 한빛사논문 |
|
|
|
|
|
| Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study |
| Lancet Resp. Med., Volume 5, Issue 11, November 2017, Pages 891-902 | https://doi.org/10.1016/S2213-2600(17)30378-8 |
| Medicine ( 2017-11-08 ) | 한빛사논문 |
|
|
|
|
 1 |
|
|
|
| Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement |
| J. Clin. Oncol., 35, no. 23 (August 2017) 2613-2618. | DOI: http://dx.doi.org/10.1200/JCO.2016.71.3701 |
| Cancer Biology/Oncology ( 2017-05-22 ) | 한빛사논문 |
|
|
|
|
|
|
|
|
|
e브릭몰 
Interview
